Discover Your
Next Breakthrough
Deep Expertise. Customized Solutions.
PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next breakthroughs for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development.
Validated Disease Models
Years of CNS Research
Client Partnerships
Who We Are
We are known for our high quality, cutting-edge translational approach to research, and our customized solutions to support our clients quantify the efficacy of their treatments before they move into the clinic.
Our capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.
Key Therapeutic Areas
Our customized preclinical testing services and industry-leading models cover a broad range of therapeutic areas to support your early-stage drug discovery.
Our Technologies and Capabilities
PsychoGenics provides validated disease models and comprehensive, integrated preclinical capabilities to discover the next breakthroughs for several disabling CNS and rare disorders.
In vivo capabilities
Biomarker Analysis
Target Engagement
Pharmacokinetics &
Pharmacodynamics (PK/PD)
Electrophysiology
PsychoGenics Cube Technologies
Revolutionizing Neuropsychiatric Drug Discovery
The Proven Power of Experience
years of experience
client relationships with more than 70% of clients returning
%
team members with a Ph.D
disease models
behavioral assays
Our Latest Updates
-
View By:
- News
- Resources
- Events
PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain
PARAMUS, N.J., October 8, 2024 –– PsychoGenics Inc. (PsychoGenics) today announced it has been awarded a contract by the National Institutes of Health (NIH) to test and identify novel investigational therapeutics for the treatment of pain. The lack of safe and...
PsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare Disorders
PARAMUS, NEW JERSEY, August 28, 2024 - PsychoGenics, a leader in AI-enabled phenotypic drug discovery, has been awarded a Fast Track Small Business Innovation Research (SBIR) grant by NIMH, worth up to $3 million over four years. This grant will support PsychoGenics...
Back to the future: From target-selective drug design to AI-enabled polypharmacology
Functional, Sensorimotor, and Cognitive Outcomes Following Unilateral MCAO in Rats
Johana Bastidas1, Karina Szyba1, Maria Ketchel1, Allison Greenyer1, Jose Beltran1, Jodi Gresack1, Afshin Ghavami11 PsychoGenics Inc., Paramus, NJ, US Stroke is a leading cause of death and long-term disability worldwide, withischemic stroke accounting for...
Behavioral and pharmacological characterization of the isosorbide dinitrate model of headache in male and female rats
Mark O. Urban 1, Yangmiao Zhang 1, Matia Ciklic 1, Christopher Conrad 2, Sarah A. Woller 2, Smriti Iyengar 2, Taleen Hanania 11 PsychoGenics Inc., Paramus, NJ, 07652, 2 Division of Translational Research, National Institutes of Neurological Disorders and Stroke,...
Spotlight on Our Tuberous Sclerosis Complex (TSC) Research and the Tsc2 KO Mouse Model
Tuberous sclerosis complex (TSC) is a genetic disorder that causes non-malignant tumors to form in many different organs, primarily in the brain, eyes, heart, kidney, skin, and lungs. Changes in the brain caused by TSC have the biggest impact on quality of life, from...